DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07029009

RecruitingPhase 2

Liraglutide Treatment in Patients With Maturity-onset Diabetes of the Young (MODY)

Investigating Enteroendocrine Dysfunction, Metabolism, and Response to Liraglutide in Patients With Maturity-onset Diabetes of the Young (MODY)

Lead sponsor

Mansa

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

50

estimated

Study population

Diabetes (other / unspecified)

Key I/E criterion

—

Primary endpoints

•HbA1c, change•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07029009
Org study ID2024-0426

Timeline

Milestones

Study start2025-05-08actual
Study first posted2025-06-19actual
Last update posted2025-12-17actual
Primary completion2026-08estimated (month precision)
Study completion2027-01estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Diabetes (other / unspecified)

Eligibility

Who can enroll

Minimum age10 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of MODY via genetic testing
•HgbA1c >6.5%

Exclusion criteria

•History of anaphylaxis to GLP-1 receptor agonists
•Already taking GLP-1 receptor agonists
•on medications within the stimulant class
•have had bariatric surgery
•personal or family history of cancer, especially medullary thyroid cancer
•personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
•known active kidney disease
•severe hypoglycemia (glucose < 50 mg/dL) within 3 months of study enrollment
•HbA1c > 10.0%
•episode of diabetic ketoacidosis (DKA) in the past 3 months
•are currently pregnant
•BMI < 18.5 kg/m2 and pediatric patients with BMI < 5th percentile

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
4
Weight & body composition
2
MASH / liver
1
Patient-reported / QoL
1

Weight & body composition

2 endpoints
Primary/protocol endpoint

BMI

Time frame:baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation

BMI, change

change from baseline, improvement

Secondary/protocol endpoint

Body fat percentage

Time frame:baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation

Total fat mass

descriptive, improvement

Glycemic / diabetes

4 endpoints
Primary/protocol endpoint

Blood sugar control - HbA1C

Time frame:Baseline and 3 months after study treatment initiation

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Secondary/protocol endpoint/low confidence

Metabolic - Blood Sugar

Time frame:Baseline through three months of study treatment

descriptive

Secondary/protocol endpoint

Enteroendocrine function - insulin

Time frame:baseline and 3 months after study treatment initiation

change from baseline, improvement

Secondary/protocol endpoint

Enteroendocrine function - c-peptide

Time frame:baseline and 3 months after study treatment initiation

C-peptide AUC

change from baseline, improvement

MASH / liver

1 endpoint
Secondary/protocol endpoint

Liver steatosis

Time frame:baseline and 3 months after treatment initiation

Liver fat content, change

change from baseline, improvement

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Enteroendocrine function - GI symptoms

Time frame:baseline, 1 month, 2 months, and final study visit 3 months after study treatment initiation

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.